PO.BCS01.12 · 生物信息与计算
SpatialTopic在黑色素瘤3D多重成像中探索肿瘤生态系统
SpatialTopic exploring tumor ecosystem in 3D multiplexed imaging of melanoma
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
背景:多重成像的进展现已能够从2D到3D刻画细胞表型,为分析复杂组织中的空间组织创造了新机会。组织结构的3D视图能够重新审视肿瘤微环境中的肿瘤-免疫相互作用,揭示在2D中可能被掩盖的、具有直接生物学和临床相关性的空间组织化生态位。
方法:我们开发了SpatialTopic¹,一种快速、可扩展、无监督的生态位检测方法,能够跨多重组织图像识别重复出现的空间模式(“主题”,topics)。SpatialTopic可在数分钟内使用适度内存分析包含数百万个细胞的数据集。以细胞类型注释作为输入,它适用于空间转录组学和蛋白质组学(例如Xenium、CosMx、IMC和CODEX)。在此,我们将SpatialTopic扩展至3D多重图像,并在来自黑色素瘤侵袭边缘²的3D CyCIF数据集上演示其适用性。我们还引入了SpatialTopic的一个监督框架,使用固定的、预定义的主题组成(“已知主题”)来预测空间主题分布,从而实现跨多个样本更可扩展的推断,并促进空间生态位与临床结局之间的关联。
结果:SpatialTopic在黑色素瘤侵袭边缘沿血管到肿瘤核心的轴线界定了四个主要主题:(1)血管主题:内皮细胞伴CD4 T细胞和巨噬细胞;(2)免疫主题:主要包括CD4 T细胞、树突状细胞,以及调节性T细胞(Treg)和B细胞;(3)肿瘤-免疫边界主题:肿瘤细胞与树突状细胞和CD4 T细胞混合;以及(4)肿瘤核心主题。在该数据集中,相较于先前的出版物²,SpatialTopic更清晰地解析了血管结构,并揭示了免疫组成从血管向肿瘤边界的渐变:在黑色素瘤侵袭前沿处巨噬细胞减少,而CD4 T细胞和树突状细胞增加。
1. Peng, X. 等。可扩展的主题建模为大规模多重成像分析解码空间组织结构。Nat. Commun. 16, 6619 (2025)。2. Yapp, C. 等。人类肿瘤中细胞状态和免疫生态位的高度多重3D刻画。Nat. Methods 22, 2180-2193 (2025)。
查看英文原文 English abstract
Background: Advances in multiplexed imaging now profile cell phenotypes from 2D to 3D, creating new opportunities to analyze spatial organization in complex tissue. A 3D view of tissue architecture enables a re-examination of tumor-immune interactions in the tumor microenvironment, revealing spatially organized niches with direct biological and clinical relevance that may be obscured in 2D.
Methods: We developed SpatialTopic 1 , a fast, scalable, unsupervised niche-detection method that identifies recurrent spatial patterns (“topics”) across multiplexed tissue images. SpatialTopic analyzes datasets with millions of cells within minutes using modest memory. With cell-type annotations as input, it applies to both spatial transcriptomics and proteomics (e.g., Xenium, CosMx, IMC and CODEX). Here, we extend SpatialTopic to 3D multiplexed images and demonstrate its applicability on a 3D CyCIF dataset from the melanoma invasive margin 2 . We also introduce a supervised framework of SpatialTopic that predicts spatial topic distributions using fixed, predefined topic compositions (“known topics”), enabling more scalable inference across multiple samples and facilitating links between spatial niches and clinical outcomes.
Results: SpatialTopic delineates four main topics along the vasculature-to-tumor-core axis at the melanoma invasive margin: (1) Vascular topic: endothelial cells with CD4 T cells and macrophages; (2) Immune topic: mainly including CD4 T cells, dendritic cells, as well as Regulatory T cells (Tregs), and B cells; (3) Tumor-immune boundary topic: tumor cells mixed with dendritic cells and CD4 T cells; and (4) Tumor core topic. In this dataset, relative to the prior publication 2 , SpatialTopic more cleanly resolves vascular structures and reveals a graded shift in immune composition from vasculature toward the tumor boundary: decreasing macrophages and increasing CD4 T cells and dendritic cells at the invasive front of melanoma.
1.Peng, X. et al. Scalable topic modelling decodes spatial tissue architecture for large-scale multiplexed imaging analysis. Nat. Commun. 16, 6619 (2025). 2.Yapp, C. et al. Highly multiplexed 3D profiling of cell states and immune niches in human tumors. Nat. Methods 22, 2180-2193 (2025).
利益披露 Disclosure
X. Peng, None.
J. Smithy,
IO Biotech ), Other, Consulting or advisory role.
Regeneron ).
Daiichi Sankyo ).
IO Biotech Other, Consulting or advisory role.
Iovance Other, Consulting or advisory role.
Bristol Myers Squibb Other, Consulting or advisory role.
Immatics ), Travel.
M. Yosofvand, None.
C. Kostrzewa,
Johnson & Johnson Stock.
F. Ehrich, None.
M. Bleile,
Sanofi Employment.
J. Lee, None.
M. A. Postow,
Bristol-Myers Squibb ), Other, Consulting or Advisory Role.
Cancer Expert Now Other, Consulting or Advisory Role.
Chugai Pharma Other, Consulting or Advisory Role.
Eisai Other, Consulting or Advisory Role.
Erasca, Inc Other, Consulting or Advisory Role.
Intellisphere Other, Consulting or Advisory Role.
Merck ), Other, Consulting or Advisory Role.
MJH Associates Other, Consulting or Advisory Role.
Nektar Other, Consulting or Advisory Role.
Novartis ), Other, Consulting or Advisory Role.
Pfizer Other, Consulting or Advisory Role.
WebMD Other, Consulting or Advisory Role.
Array BioPharma ).
Infinity Pharmaceuticals ).
Rgenix ).
M. K. Callahan,
Bristol-Myers Squibb ), Other, advisory role/consulting.
Medimmune Other, advisory role/consulting.
Immunocore Other, advisory role/consulting.
Merus Other, family member employee.
K. Panageas,
23 and Me Stock.
Vincerx Stock.
Eyepoint Stock.
Kyverna Stock.
R. Shen, None.